BerGenBio ASA: Invitation to fourth quarter 2023 results webcast
Bergen, Norway, 6 February 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the fourth quarter 2023 on Wednesday 14 February 2024. BerGenBio's senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To participate in the webcast please register in the following link: BerGenBio Q4 2023 webcast registration link